Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, monlunabant
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.
1d
on MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
devdiscourse
13h
Key Developments in Health: Novo Nordisk's Wegovy, Zevra's Breakthrough, and More
This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...
2d
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...
FierceBiotech
4d
Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
3d
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
2d
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
FierceBiotech
2d
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Wegovy
Ozempic
Denmark
Eli Lilly
European Union
Feedback